NeoGenomics Comprehensive Multimodality NeoTYPE

NeoGenomics has expanded its NeoTYPE tumor-specific profiling test menu to include new profiles for head and neck tumors, pancreatic cancer, liver cancer, sarcoma, and cancers of unknown primary (CUP). A complete analysis of somatic mutations in BRCA1 and BRCA2 are now a part of breast, ovarian, and pancreatic cancer profiling. All profiles now include analysis of PD-L1 expression by immunohistochemistry. In addition, HPV testing is being integrated with next-generation sequencing for head and neck cancer. The company is also offering profiling of sarcoma for chromosomal translocation using NGS and complete profiling of CUP using extensive immunohistochemistry, NGS of 315 genes, and nine fluorescence in situ hybridization probes.